SCHEMBL334883

SCHEMBL334883

CC(NCCN)c1cccc(NS(C)(=O)=O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.47
ADRA2C P18825 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KEAP1 Q14145 1/20 0.42
POLB P06746 1/20 0.41
NR3C1 P04150 1/20 0.41
ADRB3 P13945 3/20 0.40
LMNA P02545 2/20 0.40
ADRB2 P07550 2/20 0.40
ADRB1 P08588 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
KIF11 P52732 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335297 0.87 PRMT6 (0.46) MAPKAPK2ALDH1A1SMN1; SMN2POLBADRB3
SCHEMBL18575542 0.81 CASR (0.48) ADRA2CADRA1AALDH1A1SMN1; SMN2LMNA
SCHEMBL10243752 0.79 POLB (0.48) MAPKAPK2ALDH1A1SMN1; SMN2POLBADRB3
SCHEMBL4370199 0.77 KEAP1 (0.52) MAPKAPK2ALDH1A1SMN1; SMN2KEAP1POLB
SCHEMBL10100499 0.76 KEAP1 (0.55) MAPKAPK2ALDH1A1SMN1; SMN2KEAP1POLB
SCHEMBL11420225 0.75 ADRB3 (0.61) ADRA2CADRA1AADRA1BALDH1A1SMN1; SMN2
SCHEMBL334407 0.74 OPRK1 (0.50) MAPKAPK2ADRA2CADRA1AADRA1BALDH1A1
SCHEMBL335330 0.74 OPRK1 (0.50) MAPKAPK2ADRA2CADRA1AADRA1BALDH1A1
SCHEMBL9004208 0.74 CASR (0.42) ADRA2CADRA1AALDH1A1SMN1; SMN2ADRB3
Hydrochloric Acid SCHEMBL9216885 0.74 ADRB3 (0.59) ADRA2CADRA1AADRA1BALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MAPKAPK2 3659/4885ADRA2C 3865/4885ADRA1A 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.